Medtech Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Many New Oncology Drugs In 2012, With Prices That Test The Limits

Executive Summary

Ten thousand dollars per month for new oncology drugs has become just about standard, and the trend is not likely to go away soon. Drug makers in 2012 found pricing in oncology to be inelastic and continue to test the boundaries within which payors – and society – will play.


Related Content

Pharmacyclics/Janssen Offer Suite Of Patient Support Programs For Imbruvica
Boehringer Launches Gilotrif At $5,500/Month, Just Under Entrenched Tarceva
GSK Prices Tafinlar At $7,600/month, Undercutting Roche’s Zelboraf
Roche CEO Severin Schwan Fueled By Innovation, Emerging Markets: An Interview With PharmAsia News
Roche CEO Severin Schwan: Fueled By Innovation, Emerging Markets
Role Of Cost And Evidence In Value-Based Purchasing Highlighted By Zaltrap Price Adjustment
Questioning Stivarga’s Cost-Effectiveness In Colon Cancer
The Zaltrap Price Debate: Less Than Meets The Eye
GlaxoSmithKline Deals One-Two Punch With BRAF/MEK Pair
Dendreon Set To Ship Provenge Within A Week


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts